NO991781D0 - Retrovirale vektorer - Google Patents

Retrovirale vektorer

Info

Publication number
NO991781D0
NO991781D0 NO991781A NO991781A NO991781D0 NO 991781 D0 NO991781 D0 NO 991781D0 NO 991781 A NO991781 A NO 991781A NO 991781 A NO991781 A NO 991781A NO 991781 D0 NO991781 D0 NO 991781D0
Authority
NO
Norway
Prior art keywords
vector particle
vector
retroviral vectors
lentivirus
infecting
Prior art date
Application number
NO991781A
Other languages
English (en)
Other versions
NO991781L (no
Inventor
Alan John Kingsman
Susan Mary Kingsman
Narry Kim
Kyriacos Mitrophanous
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621680.9A external-priority patent/GB9621680D0/en
Priority claimed from GBGB9624457.9A external-priority patent/GB9624457D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Publication of NO991781D0 publication Critical patent/NO991781D0/no
Publication of NO991781L publication Critical patent/NO991781L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
NO991781A 1996-10-17 1999-04-14 Retrovirale vektorer NO991781L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9621680.9A GB9621680D0 (en) 1996-10-17 1996-10-17 Lentiviral vectors
GBGB9624457.9A GB9624457D0 (en) 1996-11-25 1996-11-25 Retroviral vectors
PCT/GB1997/002857 WO1998017815A1 (en) 1996-10-17 1997-10-17 Retroviral vectors

Publications (2)

Publication Number Publication Date
NO991781D0 true NO991781D0 (no) 1999-04-14
NO991781L NO991781L (no) 1999-06-17

Family

ID=26310246

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991781A NO991781L (no) 1996-10-17 1999-04-14 Retrovirale vektorer

Country Status (23)

Country Link
US (2) US6312682B1 (no)
EP (2) EP1041152A1 (no)
JP (2) JP4418536B2 (no)
KR (1) KR20000049251A (no)
CN (1) CN1195863C (no)
AT (1) ATE198910T1 (no)
AU (1) AU725143B2 (no)
BG (1) BG103397A (no)
CA (1) CA2267636A1 (no)
CZ (1) CZ137399A3 (no)
DE (1) DE69703974T2 (no)
DK (1) DK0904392T3 (no)
ES (1) ES2153654T3 (no)
GB (1) GB2325003B (no)
GR (1) GR3035600T3 (no)
HK (2) HK1014993A1 (no)
HU (1) HUP0000421A2 (no)
IL (1) IL129017A0 (no)
NO (1) NO991781L (no)
NZ (1) NZ334860A (no)
PL (1) PL332875A1 (no)
PT (1) PT904392E (no)
WO (1) WO1998017815A1 (no)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198784B2 (en) * 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
WO1998017815A1 (en) * 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
CA2284689C (en) * 1997-04-09 2009-10-06 Lung-Ji Chang Animal model for evaluation of vaccines
WO1998051810A1 (en) 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
ES2373406T3 (es) * 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
WO1999058701A1 (en) 1998-05-13 1999-11-18 Genetix Pharmaceuticals, Inc. Novel lentiviral packaging cells
AU4830899A (en) 1998-06-24 2000-01-10 Musc Foundation For Research Development Tissue-specific and target rna-specific ribozymes
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
WO2000066759A1 (en) * 1999-04-29 2000-11-09 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
CN1321182C (zh) * 1999-12-30 2007-06-13 卫生部艾滋病预防与控制中心 马传染性贫血病毒代表毒株的全基因克隆及其应用
EP1702983A3 (en) 2000-04-13 2007-01-10 Medical University of South Carolina Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
GB0024550D0 (no) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
WO2002087341A1 (en) * 2001-05-01 2002-11-07 Genetix Pharmaceuticals, Inc. Novel self-inactivating (sin) lentiviral vectors
IL159371A0 (en) * 2001-06-29 2004-06-01 Sloan Kettering Inst Cancer Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies
ATE527347T1 (de) * 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
IL161229A0 (en) * 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
ES2411981T3 (es) 2002-02-01 2013-07-09 Oxford Biomedica (Uk) Limited Vector lentivírico
GB0221778D0 (en) * 2002-09-19 2002-10-30 Molmed Spa Conjugate
WO2004048583A2 (en) * 2002-11-22 2004-06-10 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
GB0325379D0 (en) * 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
ES2417019T3 (es) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
WO2005112544A2 (en) 2004-02-19 2005-12-01 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
EP1732614B1 (en) * 2004-04-08 2008-12-24 Sangamo Biosciences Inc. Compositions for treating neuropathic and neurodegenerative conditions
CA2561565C (en) * 2004-04-08 2013-11-26 Sangamo Biosciences, Inc. Methods for repression of phospholamban gene and modulating cardiac contractility
WO2005118809A2 (en) * 2004-04-29 2005-12-15 The University Of North Carolina At Chapel Hill Methods and compositions for enhancing cell adhesion properties
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
DE602006013117D1 (de) 2005-04-25 2010-05-06 Merial Ltd Nipah-virus-impfstoffe
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
ES2654303T3 (es) 2007-05-04 2018-02-13 University Health Network Inmunoterapia de IL-12 contra el cáncer
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
JP2011503207A (ja) 2007-11-16 2011-01-27 サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
WO2009079373A2 (en) 2007-12-14 2009-06-25 The Regents Of The University Of California Inhibitors of calcium-activated chloride channels
ES2762864T3 (es) 2008-06-18 2020-05-26 Oxford Biomedica Ltd Purificación de virus
MX2011010406A (es) 2009-04-03 2012-01-20 Merial Ltd Vacunas aviares vectorizadas con el virus de la emfermedad de newcastle.
ES2536791T3 (es) 2010-05-28 2015-05-28 Oxford Biomedica (Uk) Ltd Administración de vectores lentivirales al cerebro
EP3156070A3 (en) 2010-08-31 2017-06-14 Merial Inc. Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
EP2701736A1 (en) 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
LT2741740T (lt) 2011-08-12 2017-08-10 Merial, Inc. Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP3889173B1 (en) 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Optimized factor viii gene
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
CA2904802C (en) * 2013-03-13 2021-03-30 Zhong Li Microvesicle and method for producing the same
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
CN106062201B (zh) 2013-10-24 2020-11-06 圣拉法埃莱医院有限公司 方法
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
BR112017027895A2 (pt) 2015-06-23 2018-11-06 Merial Inc vetores virais recombinantes contendo proteínas menores de prrsv e métodos de fabricação e utilização destes
JP7118887B2 (ja) 2015-11-23 2022-08-16 ノバルティス アーゲー 最適化されたレンチウイルス移入ベクターおよびその使用
CA3006759A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
DK3411478T3 (da) 2016-02-01 2022-09-12 Bioverativ Therapeutics Inc Optimerede faktor viii-gener
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
JP2019519250A (ja) 2016-05-10 2019-07-11 ユナイテッド ステイツ ガバメント アズ リプレゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズＵｎｉｔｅｄ Ｓｔａｔｅｓ Ｇｏｖｅｒｎｍｅｎｔ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｖｅｔｅｒａｎｓ Ａｆｆａｉｒｓ Ｈｉｖ−１感染と複製に必須な遺伝子を切断するｃｒｉｓｐｒ／ｃａｓの構築物のレンチウィルスによる送達
ES2886919T3 (es) * 2016-05-13 2021-12-21 Flash Therapeutics Partícula para la encapsidación de un sistema de ingeniería del genoma
MX2019004259A (es) 2016-10-12 2019-09-27 Bioverativ Usa Inc Anticuerpos anti-c1s y metodos de uso de los mismos.
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
KR20230119735A (ko) 2017-02-12 2023-08-16 바이오엔테크 유에스 인크. Hla 기반 방법 및 조성물, 및 이들의 용도
US11427645B2 (en) 2017-03-15 2022-08-30 Oxford Biomedica (Uk) Limited 5T4-targeting agents and methods
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
EP3645044A4 (en) 2017-06-27 2021-04-28 Neuracle Science Co., Ltd USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
WO2019003164A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
EP3645039A4 (en) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
WO2019068854A1 (en) 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
TWI823868B (zh) 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法
ES2951857T3 (es) 2017-12-22 2023-10-25 Oxford Biomedica Ltd Vector retroviral
BR112020015228A2 (pt) 2018-02-01 2020-12-29 Bioverativ Therapeutics Inc. Uso de vetores lentivirais que expressam fator viii
US11634484B2 (en) 2018-04-24 2023-04-25 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
EP3793570A2 (en) 2018-05-15 2021-03-24 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
EP3810638A1 (en) 2018-06-25 2021-04-28 Ospedale San Raffaele S.r.l. Gene therapy
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CA3115902A1 (en) 2018-10-11 2020-04-16 Ospedale San Raffaele S.R.L Selection by means of artificial transactivators
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
US20230043255A1 (en) 2018-11-14 2023-02-09 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
AU2019380517A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
CA3119341A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20220017921A1 (en) * 2018-12-04 2022-01-20 The Broad Institute, Inc. Improved vector systems for cas protein and sgrna delivery, and uses therefor
US20200199626A1 (en) 2018-12-06 2020-06-25 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021007556A (es) 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
CN115835887A (zh) 2019-03-10 2023-03-21 牛津生物医学（英国）有限公司 用于治疗帕金森病的基因治疗组合物和方法
GB201905244D0 (en) 2019-04-12 2019-05-29 Ospedale San Raffaele Method for analysisng insertion sites
GB201905301D0 (en) 2019-04-15 2019-05-29 Ospedale San Raffaele Srl Gene therapy
GB201907493D0 (en) 2019-05-28 2019-07-10 Ospedale San Raffaele Agents and methods for treating viral infections
WO2021046143A1 (en) 2019-09-03 2021-03-11 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
US20210113634A1 (en) 2019-09-30 2021-04-22 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CN114667161A (zh) 2019-11-12 2022-06-24 牛津生物医学（英国）有限公司 生产系统
CN114945409A (zh) 2020-01-13 2022-08-26 新免疫技术有限公司 用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
EP4093752A2 (en) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimeric polypeptides
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
US20240052366A1 (en) 2020-02-13 2024-02-15 Oxford Biomedica (Uk) Limited Production of Lentiviral Vectors
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
KR20220154734A (ko) 2020-03-13 2022-11-22 옥스포드 바이오메디카(유케이) 리미티드 렌티바이러스 벡터
AU2021248815A1 (en) 2020-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Targeted lipid particles and compositions and uses thereof
BR112022021918A2 (pt) 2020-04-27 2023-03-14 Univ Iowa Res Found Composições e métodos para o tratamento de fibrose cística
GB202007169D0 (en) 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
EP4171657A1 (en) 2020-06-24 2023-05-03 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
GB202010009D0 (en) 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
EP4192511A1 (en) 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Immunoconjugates targeting cd46 and methods of use thereof
WO2022047316A1 (en) 2020-08-28 2022-03-03 Sana Biotechnology, Inc. Modified anti-viral binding agents
AU2021359781A1 (en) 2020-10-12 2023-06-15 Fondazione Telethon Ets Replacement of rag1 for use in therapy
US20230398216A1 (en) 2020-10-22 2023-12-14 Lyell Immunopharma, Inc. Chimeric activation receptors
US20230398184A1 (en) 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
KR20230104175A (ko) 2020-11-05 2023-07-07 네오이뮨텍, 인코퍼레이티드 Il-7 단백질과 뉴클레오타이드 백신의 조합물을 사용한 종양의 치료 방법
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202018657D0 (en) 2020-11-26 2021-01-13 Ospedale San Raffaele Srl Agents and methods for increasing liver immune response
GB202019108D0 (en) 2020-12-03 2021-01-20 Ospedale San Raffaele Srl Vector
KR20230142704A (ko) 2020-12-14 2023-10-11 바이오엔테크 유에스 인크. 암 면역요법을 위한 조직 특이적 항원
EP4271404A2 (en) 2020-12-31 2023-11-08 Sana Biotechnology, Inc. Methods and compositions for modulating car-t activity
KR20230151513A (ko) 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Cd8 표적 바이러스 벡터의 용도
US20240101623A1 (en) 2021-02-15 2024-03-28 Ospedale San Raffaele S.R.L. Epigenetic silencing for treatment of cancer
GB202103470D0 (en) 2021-03-12 2021-04-28 Univ Bristol Promoter
CA3217247A1 (en) 2021-04-26 2022-11-03 Csl Behring L.L.C. Lentiviral vectors useful for the treatment of disease
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
EP4347620A1 (en) 2021-05-28 2024-04-10 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
EP4347826A1 (en) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
AU2022309875A1 (en) 2021-07-14 2024-01-25 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
CA3232988A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
CA3234828A1 (en) 2021-10-12 2023-04-20 Anna Villa Polynucleotides useful for correcting mutations in the rag1 gene
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114972D0 (en) 2021-10-19 2021-12-01 Ospedale San Raffaele Srl Gene therapy
WO2023077107A1 (en) 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023115039A2 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
TW202342757A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科附著醣蛋白
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
EP4209511A1 (en) 2022-01-05 2023-07-12 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies amd chimeric antigen receptors
WO2023131657A1 (en) 2022-01-05 2023-07-13 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies and chimeric antigen receptors
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
GB202204272D0 (en) 2022-03-25 2022-05-11 Ucl Business Ltd Method for engineering innate-like lymphocytes
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20230346977A1 (en) 2022-04-13 2023-11-02 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
GB202209098D0 (en) 2022-06-21 2022-08-10 Ucl Business Ltd Cyclosporine analogues
WO2024003578A1 (en) 2022-07-01 2024-01-04 The University Of Bristol Vector comprising a sequence encoding an anti-tnf antibody and an inflammation-inducible promoter
EP4303226A1 (en) 2022-07-08 2024-01-10 Ospedale San Raffaele S.r.l. Transgene cassettes and epigenetic silencers for the treatment of disorders
WO2024008950A1 (en) 2022-07-08 2024-01-11 Ospedale San Raffaele S.R.L. Transgene cassettes
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024033544A1 (en) 2022-08-12 2024-02-15 Ospedale San Raffaele S.R.L. Deglycosylation of native glycoproteins expressed on a tumor cell surface
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6170486A (en) * 1985-08-23 1987-02-26 Advanced Genetics Research Institute Defective viral vaccines
CA2084659A1 (en) * 1990-06-20 1991-12-21 Joseph G. Sodroski Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof
AU2007392A (en) * 1991-05-29 1993-01-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Eukaryotic expression vectors with regulation of rna processing
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DE69430646T2 (de) * 1993-02-17 2003-01-02 Wisconsin Alumni Res Found Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
EP0759471A4 (en) * 1994-05-10 1997-10-15 Hisamitsu Pharmaceutical Co RECOMBINANT VECTOR OF HUMAN IMMUNODEFICIENCY VIRUS AND METHOD FOR THE PRODUCTION THEREOF
US6326007B1 (en) * 1995-07-20 2001-12-04 The Regents Of The University Of California Attenuated lentivirus vectors expressing interferon
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0857217B1 (en) * 1995-10-16 2005-04-13 Dana-Farber Cancer Institute Novel expression vectors and methods of use
WO1998017815A1 (en) * 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors

Also Published As

Publication number Publication date
DE69703974D1 (de) 2001-03-01
ATE198910T1 (de) 2001-02-15
DE69703974T2 (de) 2001-07-19
DK0904392T3 (da) 2001-04-30
CA2267636A1 (en) 1998-04-30
AU4712297A (en) 1998-05-15
NO991781L (no) 1999-06-17
CN1234836A (zh) 1999-11-10
WO1998017815A1 (en) 1998-04-30
KR20000049251A (ko) 2000-07-25
GR3035600T3 (en) 2001-06-29
HK1014993A1 (en) 1999-10-08
PL332875A1 (en) 1999-10-25
ES2153654T3 (es) 2001-03-01
PT904392E (pt) 2001-06-29
JP4855504B2 (ja) 2012-01-18
GB9815778D0 (en) 1998-09-16
US6312682B1 (en) 2001-11-06
JP4418536B2 (ja) 2010-02-17
BG103397A (en) 2000-07-31
EP1041152A1 (en) 2000-10-04
EP0904392A1 (en) 1999-03-31
CZ137399A3 (cs) 1999-07-14
US20020034502A1 (en) 2002-03-21
GB2325003B (en) 2000-05-10
NZ334860A (en) 2001-02-23
GB2325003A (en) 1998-11-11
CN1195863C (zh) 2005-04-06
JP2009291205A (ja) 2009-12-17
JP2001502539A (ja) 2001-02-27
HK1016651A1 (en) 1999-11-05
HUP0000421A2 (hu) 2000-06-28
US6669936B2 (en) 2003-12-30
AU725143B2 (en) 2000-10-05
IL129017A0 (en) 2000-02-17
EP0904392B1 (en) 2001-01-24

Similar Documents

Publication Publication Date Title
ATE198910T1 (de) Retrovirale vektoren
ATE520783T1 (de) Lentivirale vektoren
Boyle et al. Avian myeloblastosis virus and E26 virus oncogene products are nuclear proteins.
CY1106513T1 (el) Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna
BR8605053A (pt) Processos para a preparacao de um polipeptidio,para a preparacao de um gene sintetico,para a preparacao de um vetor de expressao,para a preparacao de um transformante bacteriano,para a determinacao de anticorpos e de virus,para a preparacao de vacina,vacinas,anticorpos,polipeptidos,gene,vetor,transformante,kit de teste
DE69734829D1 (de) Infektiöse pseudovirale papillomavirus partikel
DE60044754D1 (de) Trans-lentivirales Vektor System
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
AU630861B2 (en) Recombinant hiv-2 polypeptides
PT880594E (pt) Vector retroviral e sua utilizacao em terapia genica
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
EP0276591A3 (en) Viral vector and recombinant dna coding for the p25 protein of the aids virus
ATE393819T1 (de) Verwendungen von immortalisierten, homozygoten stat1-defizienten säugerzelllinien

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application